BioInformant

Your Global Leader in Stem Cell Market Research

Home » mesenchymal stem cells » Page 3

Cynata Therapeutics to Test Proprietary MSC Manufacturing Process in GvHD Clinical Trial

By Leave a Comment

Cynata Announces First Clinical Study Utilizing MSCs Manufactured by Cymerus™ Platform

Cynata TherapeuticsCynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange  (ASX: CYP), released major news today by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD.

The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study.  [Read more…]

Longeveron Begins Enrollment of Second Cohort of Phase 1 Alzheimer’s Disease Trial

By Leave a Comment

MIAMI, May 10, 2017 — Longeveron companyLongeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.

The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.

[Read more…]

Analyzing the Mesenchymal Stem Cell (MSC) Market Using Social Analytics

By 1 Comment

Twitter Metrics for BioInformant - @StemCellMartketOne of the ways to use market intelligence to analyze trends within the mesenchymal stem cell (MSC) market is to assess how the cell type is being discussed on leading social media platforms, such as Twitter.

Twitter.com is one of the most widely used social media platforms today. It has with 316 million monthly active users and 500 million Tweets sent per day, according to Twitter’s company statistics. 

It is also the 9th most visited website in the world, an impressive accomplishment.

Social Analytics Reveal Key Trends about Mesenchymal Stem Cell (MSC) Research

The figure below shows a hashtag map for the term “#mesenchymal.” It was produced using the  social analytics platform Hashtagify.me.

The linked topics shown as spokes in this figure represent the top hashtags that are used together with the hashtag “#mesenchymal” on Twitter.
[Read more…]

Mesoblast Securing IP Portfolio for Use of Mesenchymal Precursor Cells

By Leave a Comment

Mesoblast has been granted a key patent by the United States Patent and Trademark Office (USPTO) for use of its Mesenchymal Precursor Cells (MPCs) in the treatment of rheumatic diseases, including rheumatoid arthritis (RA). Mesoblast is global company that specializes in developing cell-based therapies that utilize mesenchymal precursor cells (MPCs) and mesenchymal stem cells (MSCs).

The Company’s patent portfolio in the United States for the treatment of RA and related conditions “comprises the newly and recently granted patents, US 9,381,216 and US 9,265,796, which cover treatment of rheumatic diseases by administration of STRO-1 positive MPCs.”

According to Dr. Allan Gibofsky, Professor at Weill Cornell Medical College, “The trial used standardized parameters consistent with United States Food and Drug Administration (FDA) guidance for RA product development. Importantly, there was consistency observed in the dose-related responses for clinical symptoms, physical function and disease activity parameters at 12 weeks in line with the trial’s pre-specified efficacy endpoints.”

To learn more, view the Mesoblast press announcement.

Introduction to Cord Tissue-Derived Mesenchymal Stem Cells (CT-MSCs)

By Leave a Comment

The past few years have seen major change within the global cord blood banking industry, with new trends emerging, shifts in public perception toward cord blood storage, improving techniques for the use of cord blood in cellular therapy, and more.

The post below discusses important trends in umbilical cord tissue storage and the degree to which these trends are impacting cord blood market participants.

How the Cord Tissue Banking Market Began

The storage of umbilical cord tissue has been a significant trend within the cord blood industry over the past few years. The reason to store both umbilical cord blood and tissue is that they contain different types of stem cells, each with the potential to treat different types of injury or disease. In cord tissue banking, 4-8 cm of the umbilical cord is collected, placed in the tissue collection kit, and transported to a cord blood bank for processing and storage. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0